Clearmind patent application for dyskinesia treatment published in Japan

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. BA
5. STX
6. V
7. CSGP
8. LSTR
9. UPS
10. KIDS

Go back to Clearmind patent application for dyskinesia treatment published in Japan

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

October 8, 2026 7:32 AM EDT

Published patent application covers 3-MMC-based treatment of dyskinesia, including in combination with Palmitoylethanolamide (PEA)

Vancouver, Canada, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the Company), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (AUD), today announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements. The published patent application covers the use of 3-Methylmethcathinone (3-MMC) for preventing, treating, or reducing dyskinesia symptoms, including... More